Led/participated in Atsena Therapeutics' oversubscribed $150 million Series C for ocular gene therapy programs.
Atsena Therapeutics is a clinical-stage gene therapy company developing first- and best-in-class treatments for inherited retinal diseases
Atsena Therapeutics is a clinical-stage gene therapy company developing first- and best-in-class treatments for inherited retinal diseases. The company focuses on reversing or preventing blindness through innovative genetic medicines.